 Shanta Zimmer
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 622 | 1.150 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 148 | 0.980 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 548 | 0.710 |
Why?
| | Physicians, Women | 1 | 2020 | 83 | 0.620 |
Why?
| | Vulnerable Populations | 1 | 2020 | 163 | 0.610 |
Why?
| | Coronavirus Infections | 2 | 2023 | 364 | 0.600 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 23 | 0.580 |
Why?
| | Communicable Diseases | 1 | 2020 | 159 | 0.580 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 24 | 0.580 |
Why?
| | Internship and Residency | 6 | 2019 | 1147 | 0.530 |
Why?
| | Professional Misconduct | 1 | 2016 | 13 | 0.500 |
Why?
| | Pennsylvania | 8 | 2021 | 116 | 0.480 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 6 | 0.480 |
Why?
| | Faculty | 1 | 2016 | 147 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.460 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 55 | 0.460 |
Why?
| | Curriculum | 4 | 2024 | 992 | 0.450 |
Why?
| | Internal Medicine | 4 | 2018 | 265 | 0.420 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 165 | 0.370 |
Why?
| | Influenza Vaccines | 6 | 2011 | 539 | 0.360 |
Why?
| | Physicians | 3 | 2016 | 910 | 0.350 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 486 | 0.330 |
Why?
| | Computer Simulation | 9 | 2012 | 978 | 0.320 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 188 | 0.320 |
Why?
| | Reassortant Viruses | 1 | 2009 | 7 | 0.320 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 273 | 0.320 |
Why?
| | Students, Medical | 2 | 2024 | 348 | 0.310 |
Why?
| | Zoonoses | 1 | 2009 | 33 | 0.310 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 36 | 0.310 |
Why?
| | Lipid A | 3 | 2007 | 29 | 0.300 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 67 | 0.300 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 390 | 0.280 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.270 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.270 |
Why?
| | Dermatomycoses | 1 | 2007 | 7 | 0.270 |
Why?
| | Paclitaxel | 1 | 2008 | 230 | 0.270 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 191 | 0.270 |
Why?
| | Oxazolidinones | 2 | 2004 | 15 | 0.260 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 214 | 0.260 |
Why?
| | Acetamides | 2 | 2004 | 36 | 0.260 |
Why?
| | Thiazoles | 1 | 2007 | 123 | 0.260 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 70 | 0.250 |
Why?
| | Triazoles | 1 | 2007 | 147 | 0.240 |
Why?
| | Humans | 50 | 2024 | 137585 | 0.240 |
Why?
| | Fungi | 1 | 2007 | 144 | 0.240 |
Why?
| | Leadership | 2 | 2020 | 388 | 0.240 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 90 | 0.240 |
Why?
| | History, 21st Century | 2 | 2020 | 213 | 0.230 |
Why?
| | Schools | 4 | 2021 | 461 | 0.230 |
Why?
| | Disease Outbreaks | 5 | 2010 | 395 | 0.230 |
Why?
| | History, 20th Century | 2 | 2020 | 325 | 0.220 |
Why?
| | Exploratory Behavior | 1 | 2024 | 92 | 0.210 |
Why?
| | Medical Tourism | 1 | 2023 | 8 | 0.210 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.210 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 5 | 0.210 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 6 | 0.210 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 26 | 0.200 |
Why?
| | Models, Molecular | 1 | 2008 | 1570 | 0.200 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 41 | 0.200 |
Why?
| | Sulfonamides | 1 | 2007 | 513 | 0.200 |
Why?
| | Clinical Clerkship | 1 | 2024 | 101 | 0.200 |
Why?
| | Meningitis | 1 | 2023 | 79 | 0.190 |
Why?
| | Models, Economic | 3 | 2012 | 58 | 0.190 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 213 | 0.190 |
Why?
| | Viruses | 1 | 2023 | 113 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 117 | 0.180 |
Why?
| | Emergency Responders | 1 | 2021 | 36 | 0.170 |
Why?
| | Program Evaluation | 3 | 2019 | 898 | 0.170 |
Why?
| | Crowding | 1 | 2020 | 35 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2020 | 67 | 0.160 |
Why?
| | Shoulder | 1 | 2020 | 89 | 0.160 |
Why?
| | Frail Elderly | 1 | 2020 | 131 | 0.150 |
Why?
| | Prisons | 1 | 2020 | 81 | 0.150 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 20 | 0.150 |
Why?
| | Virus Diseases | 1 | 2021 | 212 | 0.150 |
Why?
| | Financing, Organized | 1 | 2018 | 35 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 363 | 0.150 |
Why?
| | Minority Groups | 1 | 2020 | 266 | 0.150 |
Why?
| | Nursing Homes | 1 | 2020 | 181 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 740 | 0.140 |
Why?
| | Adult | 18 | 2023 | 37929 | 0.140 |
Why?
| | Faculty, Medical | 2 | 2018 | 283 | 0.140 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 128 | 0.140 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 167 | 0.140 |
Why?
| | Clinical Competence | 3 | 2024 | 1118 | 0.130 |
Why?
| | Preceptorship | 1 | 2017 | 66 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.130 |
Why?
| | Anesthesiology | 1 | 2018 | 87 | 0.130 |
Why?
| | Urban Population | 1 | 2020 | 479 | 0.130 |
Why?
| | Population Surveillance | 2 | 2011 | 482 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2020 | 341 | 0.130 |
Why?
| | Societies, Medical | 1 | 2020 | 820 | 0.120 |
Why?
| | Rural Population | 1 | 2020 | 563 | 0.120 |
Why?
| | HIV Infections | 2 | 2022 | 2836 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.120 |
Why?
| | Female | 18 | 2022 | 73304 | 0.120 |
Why?
| | Endotoxins | 2 | 2007 | 220 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 284 | 0.120 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 778 | 0.120 |
Why?
| | Cardiology | 1 | 2017 | 274 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2019 | 485 | 0.110 |
Why?
| | Antiviral Agents | 2 | 2011 | 744 | 0.110 |
Why?
| | United States | 7 | 2020 | 14841 | 0.110 |
Why?
| | Binding Sites | 2 | 2008 | 1303 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1353 | 0.110 |
Why?
| | Male | 17 | 2022 | 67762 | 0.100 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.100 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 49 | 0.100 |
Why?
| | Macrophage Activation | 2 | 2005 | 201 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 96 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1809 | 0.100 |
Why?
| | Macrophages | 4 | 2008 | 1547 | 0.100 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 385 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2189 | 0.090 |
Why?
| | Patients | 1 | 2013 | 175 | 0.090 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 500 | 0.090 |
Why?
| | Social Support | 1 | 2016 | 618 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 197 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2021 | 625 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5778 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Poverty Areas | 1 | 2011 | 39 | 0.090 |
Why?
| | Patient Preference | 1 | 2013 | 191 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2426 | 0.090 |
Why?
| | Guanidines | 1 | 2011 | 39 | 0.090 |
Why?
| | Aged | 8 | 2020 | 23961 | 0.090 |
Why?
| | Cyclopentanes | 1 | 2011 | 19 | 0.090 |
Why?
| | Health Care Costs | 2 | 2011 | 398 | 0.090 |
Why?
| | Hemagglutinins | 1 | 2010 | 9 | 0.090 |
Why?
| | Hospitalization | 1 | 2020 | 2199 | 0.090 |
Why?
| | Quality Improvement | 1 | 2019 | 1178 | 0.080 |
Why?
| | Students | 1 | 2016 | 622 | 0.080 |
Why?
| | Clostridium Infections | 1 | 2011 | 73 | 0.080 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 115 | 0.080 |
Why?
| | Communication | 1 | 2016 | 879 | 0.080 |
Why?
| | Quarantine | 1 | 2010 | 30 | 0.080 |
Why?
| | Occupational Health Services | 1 | 2009 | 32 | 0.080 |
Why?
| | Health Care Rationing | 1 | 2010 | 59 | 0.080 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.080 |
Why?
| | Antigenic Variation | 1 | 2009 | 10 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 226 | 0.080 |
Why?
| | Seasons | 2 | 2023 | 547 | 0.080 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 400 | 0.080 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 234 | 0.080 |
Why?
| | Antibody Specificity | 1 | 2009 | 189 | 0.080 |
Why?
| | Young Adult | 7 | 2020 | 13209 | 0.080 |
Why?
| | Birds | 1 | 2009 | 93 | 0.070 |
Why?
| | Cross Infection | 1 | 2011 | 256 | 0.070 |
Why?
| | Primary Prevention | 1 | 2010 | 196 | 0.070 |
Why?
| | Genome, Viral | 1 | 2009 | 144 | 0.070 |
Why?
| | Child | 9 | 2023 | 21935 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 628 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 47 | 0.070 |
Why?
| | Child, Preschool | 7 | 2021 | 11074 | 0.070 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 11 | 0.070 |
Why?
| | Pichia | 1 | 2007 | 20 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 374 | 0.070 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.070 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 3 | 0.070 |
Why?
| | Cell Line | 3 | 2008 | 2847 | 0.070 |
Why?
| | Nitro Compounds | 1 | 2007 | 6 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 2295 | 0.070 |
Why?
| | Surface Properties | 1 | 2008 | 413 | 0.070 |
Why?
| | Tubulin | 1 | 2008 | 144 | 0.070 |
Why?
| | Species Specificity | 1 | 2008 | 585 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2011 | 435 | 0.070 |
Why?
| | Linezolid | 2 | 2004 | 23 | 0.070 |
Why?
| | Swine | 1 | 2009 | 775 | 0.070 |
Why?
| | District of Columbia | 3 | 2011 | 28 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2008 | 169 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2007 | 136 | 0.060 |
Why?
| | Phylogeny | 1 | 2010 | 904 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1793 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 861 | 0.060 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 16 | 0.060 |
Why?
| | Enterococcus | 1 | 2005 | 23 | 0.060 |
Why?
| | Adolescent | 7 | 2022 | 21513 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 83 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 493 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 945 | 0.060 |
Why?
| | Efficiency | 2 | 2019 | 99 | 0.060 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 65 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2057 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 216 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 886 | 0.050 |
Why?
| | Middle Aged | 9 | 2021 | 33479 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2011 | 986 | 0.050 |
Why?
| | Animals | 5 | 2009 | 36940 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 85 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 128 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1242 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 214 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7635 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2900 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 1070 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 669 | 0.050 |
Why?
| | Protein Binding | 1 | 2008 | 2224 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 255 | 0.050 |
Why?
| | Infant | 4 | 2012 | 9465 | 0.040 |
Why?
| | Influenza B virus | 1 | 2021 | 44 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 27 | 0.040 |
Why?
| | Monte Carlo Method | 2 | 2011 | 148 | 0.040 |
Why?
| | Absenteeism | 1 | 2021 | 49 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 184 | 0.040 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 13 | 0.040 |
Why?
| | Learning | 1 | 2024 | 409 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10388 | 0.040 |
Why?
| | Ecology | 1 | 2021 | 118 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4193 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 594 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1024 | 0.040 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 591 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 257 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 679 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 1040 | 0.040 |
Why?
| | Schools, Medical | 1 | 2019 | 147 | 0.040 |
Why?
| | Medication Adherence | 1 | 2022 | 467 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1062 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 173 | 0.030 |
Why?
| | Models, Educational | 1 | 2017 | 93 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2018 | 170 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 893 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5742 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 645 | 0.030 |
Why?
| | Mice | 3 | 2008 | 17787 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2074 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 289 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 522 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 827 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 6079 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 322 | 0.030 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 185 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3295 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 692 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2389 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 786 | 0.020 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 23 | 0.020 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 35 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5079 | 0.020 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 1 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 93 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 70 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4565 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 113 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 673 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 184 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 521 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 329 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 174 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 16 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 308 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 146 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 439 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 413 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 169 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 213 | 0.020 |
Why?
| | Travel | 1 | 2010 | 130 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 140 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1329 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 15657 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 364 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 261 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 351 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 200 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 421 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1289 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1916 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1710 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2010 | 579 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 570 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 73 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 269 | 0.010 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 99 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1459 | 0.010 |
Why?
| | Growth | 1 | 2004 | 60 | 0.010 |
Why?
| | Incidence | 1 | 2011 | 2804 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2008 | 956 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2004 | 16 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 24 | 0.010 |
Why?
| | Sugar Acids | 1 | 2004 | 5 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 154 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1783 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 115 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10811 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1381 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 570 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 430 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5472 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3556 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 915 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6828 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2085 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|